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Abstract Synchronization used to study cell cycle progression
may change the characteristics of rapidly proliferating cells. By
combining time-lapse, quantitative fluorescent microscopy and
microinjection, we have established a method to analyze the cell
cycle progression of individual cells without synchronization.
This new approach revealed that rapidly growing NIH3T3 cells
make a Ras-dependent commitment for completion of the next
cell cycle while they are in G2 phase of the preceding cell cycle.
Thus, Ras activity during G2 phase induces cyclin D1 expression.
This expression continues through the next G1 phase even in the
absence of Ras activity, and drives cells into S phase. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Multiple molecular events are required for transition from
G1 to S phase [1^3]. Most of these were identi¢ed by analyz-
ing quiescent cells stimulated to enter the cell cycle following
mitogen stimulation. Results obtained during this cell cycle re-
entry may apply in situations such as wound healing where
many quiescent cells are required to re-enter the cell cycle and
proliferate rapidly. However, there are many lines of evidence
indicating a di¡erence between this type of cell cycle re-initia-
tion and continuous cell cycle progression. It is important to
analyze the molecular events that control continuous cell cycle
progression to understand the cell cycle control of continu-
ously cycling cells from tissues such as skin, gut, bone mar-
row, and from cancer. Unfortunately, methods of cell cycle
synchronization may not be ideal in the analysis of cell cycle
progression because synchronization itself usually interrupts
the cell cycle. In order to avoid such possible complications,
by combining time-lapse, microinjection and quantitative £u-
orocytometry, we developed a cell cycle analysis method
which does not require synchronization. In this review, we
discuss the necessity of such methods, how they work and
the results obtained. In rapidly cycling cells we observed a
completely di¡erent sequence of molecular events from those
observed in synchronous G0/S transition.
2. Growth phase transition from G0 to S phase
2.1. Restriction point
When cells are deprived of mitogens they exit the cell cycle
and enter a quiescent state with G1 DNA content. This con-
dition is often called G0 phase. When mitogens become avail-
able again to quiescent cells, they resume the cell cycle in a
synchronous manner. During this re-entry process, mitogens
are only required until a point located in mid-to-late G1
phase. Beyond this point, cells can complete one cell division
cycle without growth factors. In other words, at this point the
cells make a decision to complete the rest of the cell cycle and
produce daughter cells. This critical commitment point is re-
ferred as the ‘restriction point’ [4]. The restriction point also
coincides with the last point of the cell cycle in which essential
amino acids or protein synthesis is required for the comple-
tion of cell division [5].
2.2. Molecular mechanism governing the restriction point
What is the molecular basis of the restriction point? Upon
ligand binding, growth factor receptors dimerize and phos-
phorylate tyrosine residues in their own cytoplasmic domains.
These phosphorylated tyrosine residues recruit signaling mol-
ecules to the membrane. Among the recruited molecules are
nucleotide exchange factors for Ras protein, which promote
binding to GTP [1]. The GTP-bound form of Ras actively
signals to multiple downstream e¡ectors, including the MAP
kinase pathway which is vital in mediating the mitogenic ac-
tivity of Ras protein [6,7]. This pathway, together with other
pathways, phosphorylates and activates transcription factors
to induce numerous genes [8]. Cyclin D1 is such a gene in-
duced by mitogens through Ras activity.
Cyclin D1 was ¢rst identi¢ed as a delayed immediate gene
induced by mitogenic stimulation [9]. Its promoter contains
mitogen-responsive Ets and AP-1 binding sites [10]. The tan-
dem occurrence of Ets and AP-1 sites has been shown to
respond to Ras signaling [11]. In fact, Ras has been reported
as a potent inducer of cyclin D1 expression [12^14]. Once
induced, cyclin D1 protein forms complexes with cyclin-
dependent kinase (CDK) 4 or 6 [15]. Cyclin association is
required for CDK activity. Cyclin D1-associated kinases
play an essential role in governing G1/S transition [16]. Cyclin
D1 also titrates the inhibitors of other CDKs by physical
association, resulting in their activation to further facilitate
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G1/S transition [2]. Because of its responsiveness to mitogens
and its requirement during cell cycle progression, cyclin D1 is
a pivotal molecule connecting the mitogenic signaling system
to the cell cycle control machinery [17].
Cyclin D1-associated CDKs play a vital role in phosphor-
ylating the retinoblastoma protein (Rb). Rb is a well-estab-
lished in vivo substrate of cyclin D1/CDK complexes [18,19].
Underphosphorylated forms of Rb bind the E2F/DP tran-
scription factor complexes, and repress their transcriptional
activity by recruiting repressor molecules, such as histone de-
acetylase and/or nucleosome remodeling complex to the prox-
imity of the promoter regions containing the E2F/DP binding
motif [20^22]. E2F/DP binding sites have been identi¢ed in
promoters of many genes whose products are essential for
G1/S transition (cyclin E or A) or DNA synthesis (dihydro-
folate reductase, DNA polymerase K, cdc 6, etc.) [23]. There-
fore, when Rb is underphosphorylated, the expression of these
genes required for S phase is suppressed. Upon phosphoryla-
tion by cyclin D1/CDK complexes, E2F/DP complexes are
released from Rb and activate target genes. Once E2F/DP
target genes are expressed, growth factors are no longer re-
quired for entry into S phase. After the initiation of DNA
synthesis, cells are committed to complete the cell cycle
through mitosis without mitogens or de novo protein synthe-
sis [3]. In this way, the signaling pathway from mitogens
through Ras and cyclin D1 to Rb is believed to play an
important role in controlling the restriction point observed
during the growth phase transition from G0 to S phase. There
are biological evidences to support this Ras^cyclin D1^Rb
hierarchy. Forced expression of cyclin D1 can overcome
growth suppression induced by dominant negative Ras [12].
Ras and cyclin D1 are no longer required for G1/S transition
in Rb compromised cells [24^26].
2.3. Ras requirements during G0/S transition
During the G0/S transition, Ras has been reported to play
critical roles at multiple points. Biochemical analyses detected
two peaks of Ras activity as cells progress from G0 to S
phase. The ¢rst peak is detected soon after serum stimulation,
and the second one at mid-to-late G1 phase [27,28]. Biological
analyses also indicate the requirement of the Ras activity
multiple times during the re-entry into the cell cycle from
quiescence [29].
3. The necessity for a new method to analyze progression
through cell cycle without synchronization
The signaling interactions described above were identi¢ed in
synchronous cultures of mitogen restimulated quiescent cells.
There are, however, evidences to suggest that cell cycle control
in continuously proliferating cells is quite di¡erent than in
quiescent cells stimulated to re-enter the cell cycle. For exam-
ple, (1) c-Fos, a target gene of the Ras signaling pathway, is
rapidly induced following mitogen stimulation and is essential
for cell cycle re-entry from quiescence. This gene, however, is
not expressed at any time in actively cycling cells. Further-
more, neutralizing anti-c-Fos antibody (Ab) blocks re-entry
into the cell cycle but has no e¡ect in cycling cells [30]. (2)
In Rb 3/3 cells, Ras is dispensable for continuous cell cycle
progression, but is essential for transition from quiescence to
S phase [26]. (3) The expression of proteins involved in the
replication complex such as cdc6, orc1 and mcm, are ex-
pressed at low levels in quiescent cells, but are detected in
all continuously cycling cells regardless of cell cycle position
[31^35]. (4) C-myc expression peaks in G1 phase during the
re-entry into cell cycle, but its expression in cycling cells is
constant [36^38].
All these examples indicate that the mechanism of cell cycle
control in continuous cycle may be very di¡erent from that
observed in the G0/S transition. The above facts emphasize
the need to study the control of cell cycle progression in con-
tinuously cycling cells. Unfortunately, such studies are com-
plicated by the fact that continuously cycling cells have to be
synchronized before analysis. Synchronization usually re-
quires reversible growth arrest which might alter signaling
patterns in the treated cells. For instance, reagents such as
transforming growth factor L or nocodazole induce growth-
arresting molecules, which are normally maintained at low
levels during continuous cell cycle progression. Synchroniza-
tion by means of selecting cells in speci¢c cell cycle phases
includes mitotic shake o¡ and centrifugal elutriation. How-
ever, in cells collected by mitotic shake o¡, the G1 phase
period doubles in length [39]. The G1 population collected
from rapidly growing culture by centrifugal elutriation has
been reported to have some properties of G0 cells [40]. Both
methods require the detachment of the cells from a plate,
which will disrupt signaling events essential for cell cycle pro-
gression [41]. Clearly, it would be best to avoid synchroniza-
tion in the analysis of the cell cycle progression of continu-
ously growing cells. Zetterberg and Larsson used time-lapse
movies to circumvent the need for synchronization, to study
the restriction point in rapidly cycling cells [42]. The cell cycle
phase of individual cells was predicted by determining the
time since each cell had passed through mitosis. We have
combined this time-lapse technique with microinjection and
quantitative £uorocytometry to determine the requirement
point for Ras in rapidly proliferating cells.
4. Methods to analyze cell cycle without synchronization
We will begin with a description of the technical approach
utilized in the study of proliferative signaling in continuously
cycling cells. The cell cycle position of individual cells was
determined by time-lapse and quantitative £uorocytometry.
Microinjection in combination with time-lapse allowed us to
manipulate signaling molecules at speci¢ed cell cycle phases.
We could determine the expression levels of proteins of inter-
est using quantitative immuno£uorescence. Below are brief
descriptions of each technique. Detailed information is de-
scribed elsewhere [39,43^45].
Time-lapse movies were made of cells in an environmental
chamber containing 5% CO2 at 37‡C on a microscope stage.
Time-lapse images were captured with a CCD camera con-
trolled by the NIH Image program [44,45]. By determining
the time passed since mitosis (age of the cell), we could predict
the cell cycle phase of each cell [39,42,44,45]. Time-lapse mov-
ies were also used to analyze cell migration.
In order to manipulate the activity of speci¢c molecules of
interest, we microinjected neutralizing antibodies, or constitu-
tively active molecules [46^49]. Microinjection is ideal in stud-
ies of cell cycle progression, because a speci¢c signaling event
can be targeted in a short period of time. For example, neu-
tralizing anti-Ras Ab can inhibit Erk activation within 20^30
min [44] ; its inhibitory e¡ect on Ras-dependent cell migration
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[50] is detected within half an hour (Fig. 1). Injected onco-
genic Ras induces a Ras-responsive reporter gene within 3 h
[51]. Because of such rapid action, the e¡ects of these manip-
ulations can be assessed within a single cell cycle period. For
example, in rapidly growing NIH3T3 cells with doubling
times of 16^18 h, if the injection was done within a couple
of hours after mitosis the cell was most likely in G1 phase;
cells which received injections between 5 and 12 h after mi-
tosis were in S phase at the time of injection; after 12 h
following mitosis, most cells were in G2 phase [44,45]. This
rapid action of microinjected molecules is advantageous over
the other methods such as transfection, or viral transduction
which require many hours to be e¡ective.
Because time-lapse analyses are time consuming and involve
limited numbers of cells, we also utilized quantitative £uoro-
cytometry and digital image analysis to determine the DNA
content of individual cells. 4P,6-Diamidino-2-phenylindole, di-
hydrochloride (DAPI) £uorescence values were proportional
to DNA content [43], allowing us to determine the ¢nal cell
cycle phase of individual cells in an asynchronous culture.
These techniques were also able to determine the expression
levels of proteins in individual cells stained by indirect immu-
no£uorescence. The relative protein expression levels deter-
mined by these methods were in good agreement with those
obtained by quantitative Western blot analyses [39,43].
5. The Ras requirement during continuous cell cycle
5.1. Ras is required during the G2 phase for the next cell cycle
In order to analyze the Ras requirement in rapidly growing
cells, we injected anti-Ras into rapidly cycling NIH3T3 cells,
which express functional Rb. Before injection, a time-lapse
movie was made to determine the cell cycle phase of individ-
ual cells at the time of injection. The fate of the injected cells
was monitored in a second time-lapse movie of the injected
area. Studies of G0/S transition predict that anti-Ras injection
during G1 phase would block cell cycle progression. In asyn-
chronous culture, however, we found that the majority of the
cells went through mitosis once following anti-Ras Ab injec-
tion regardless of their cell cycle position at the time of in-
jection. Cells continued to progress through one cell cycle and
completed mitosis once, even if anti-Ras Ab was introduced
during G1 phase. The fact that most of the cells accomplish
one cell cycle without signi¢cant delay indicates that there was
no requirement for Ras during any cell cycle phase in contin-
uously cycling cells [44]. Although cells without Ras activity
divided once, almost none of them divided a second time. At
the end of the experiment, most of the injected cells were
arrested in G1 phase as judged by the DNA content [43,44].
These data indicate that, unlike re-entry into the cell cycle
from quiescence where Ras is required during G1, in asyn-
chronous cells Ras activity is required prior to mitosis to
complete the next entire cell cycle. The progression from G1
to S phase, however, is still under the control of Rb as cyclin
D1 was required just prior to the beginning of S phase
[44]. The cyclin D1 result was obtained by microinjecting
neutralizing anti-cyclin D1 Ab. In this case, cells injected
during G1 phase were e¡ectively blocked from entering into
S phase.
Analogous determinations were performed by removing se-
rum rather than injecting neutralizing antibodies. With this
approach the serum-dependent commitment was observed
during early G1 phase [42,44,52]. This indicates that mitogens
are required after Ras activity in cycling cells. The order of
Ras requirement in G2 phase and serum requirement in early
G1 phase seems to be opposite to what is predicted by the fact
that Ras functions downstream of mitogens. However, in ad-
dition to Ras, many signaling pathways have been identi¢ed
to be activated by mitogens [53,54]. The signaling from
growth factor receptor to myc through Src family tyrosine
kinases constitutes an essential mitogenic signaling pathway
independent of the Ras pathway [55]. The major mitogenic
activity in serum is most likely to be platelet-derived lysophos-
phatidic acid, which signals through trimeric G proteins [56].
Trimeric G protein-mediated mitogenic signaling also stimu-
lates multiple downstream molecules including Src and Ras,
which are common among those activated by peptide growth
factors [57]. Therefore, the serum requirement during early G1
phase of the continuous cell cycle suggests the presence of
such mitogen-dependent, Ras-independent, essential pathways
playing important roles in G1/S transition.
5.2. Our hypothesis
These observations suggest that in rapidly proliferating
cells, Ras activity induces something essential for the next
G1/S transition, but it does so prior to mitosis, during G2
phase. Moreover, this Ras-induced factor must remain active
through mitosis and G1 phase to induce S phase entry even in
the continued absence of Ras activity. Once cells start DNA
synthesis, they will complete a cell cycle unless they are ex-
posed to genotoxic reagents, which induce checkpoint-depen-
dent arrests [3]. We hypothesized that this Ras-induced factor
could be cyclin D1 for the following reasons: (1) cyclin D1 is
induced by Ras [10,13,14]. (2) Cyclin D1 is required to abro-
gate Rb growth suppressive functions for G1/S transition
Fig. 1. Migration of Ras-transformed cells following injection of
anti-Ras or anti-cyclin D1 antibodies. Neutralizing anti-Ras Ab im-
mediately blocks cell migration. Ras-transformed cells have high cell
motility due to constitutive Ras activity [50]. Motility of Ras-trans-
formed NIH3T3 cells was monitored by time-lapse for several
hours, at which time cells were injected with either anti-Ras (open
square) or anti-cyclin D1 Ab (closed circle). Soon after the injection
(0 h), these cells were observed with a second time-lapse analysis to
determine post-injection migration characteristics. Approximately 50
cells were analyzed at each time point and mean values are plotted.
The motility of the anti-Ras Ab-injected cells was immediately sup-
pressed and remained at a low level, whereas control injection re-
sulted in only a brief suppression of migration. This indicates that
anti-Ras Ab injection blocks Ras activity in a short period even in
the cells expressing constitutively active Ras.
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[16,24,58]. (3) Cyclin D1 can substitute, at least in part, for
the Ras requirement during cell proliferation [12,26]. We
therefore predicted that during continuous cell cycle progres-
sion, a cell senses favorable growth conditions during G2
phase and responds by activating Ras. The activated Ras
then induces cyclin D1 during G2 phase. Once induced during
G2 phase, the expression of cyclin D1 becomes independent of
Ras through G1 phase allowing cells to transit from G1 to S
phase in the absence of Ras activity.
5.3. Predictions from our hypothesis
Our hypothesis predicts the following in rapidly growing
cultures:
1. Cyclin D1 should be expressed at high levels in G2 phase.
2. This G2 phase expression is Ras-dependent.
3. The subsequent expression of cyclin D1 during G1 is Ras-
independent.
4. Forced expression of cyclin D1 can substitute for Ras ac-
tivity in cycling cells.
5.4. Con¢rmation of our hypothesis
To test our hypothesis, we utilized quantitative immuno-
£uorescence techniques to determine cyclin D1 expression lev-
els together with the cell cycle position of individual cells in an
asynchronous culture. As our hypothesis predicted, cyclin D1
was expressed at high levels not only in G1 phase but also in
G2 phase (Fig. 2D). The expression levels during S phase are
low, probably due to the repressive activity of free E2F [59] or
inactivation of the growth inhibitory activity of Rb in S phase
[60]. This pattern of cyclin D1 expression is not restricted to
rapidly growing, immortalized 3T3 cells. The same pattern
was observed in asynchronous cultures of mouse embryonic
¢broblast (MEF) as well as in human diploid ¢broblasts (Fig.
2). A similar expression pattern through the cell cycle phases
have been documented for cyclin D1 message [61]. Upon ran-
dom injection of neutralizing Ab against Ras protein, the
expression of cyclin D1 in G2 phase was ¢rst suppressed
(6 h after the injection), while G1 phase expression persisted
for a longer period of time [43]. To con¢rm the Ras depend-
ency more clearly, the S phase cells of an asynchronous
NIH3T3 culture were tagged by a bromodeoxyuridine
Fig. 2. Cyclin D1 is expressed at high levels in G2 phase. Rapidly growing cultures of the indicated cells were ¢xed and stained for cyclin D1
with indirect immuno£uorescence using monoclonal anti-cyclin D1 antibodies, the clone 72-13G for mouse cells and the clone DCS-6 for MRC
5 cells. DNA was stained with DAPI and BrdU incorporation was detected with indirect immuno£uorescence. DNA content and the expression
levels of cyclin D1 of individual cells were determined using digital image analysis as described [43]. A: Cyclin D1 +/+ MEF. B: Cyclin
D1 3/3 MEF. C: MRC 5 cells, human diploid ¢broblasts. D: NIH3T3 cells. Just prior to ¢xing, NIH3T3 cells were pulsed with BrdU for
30 min to identify S phase cells. S phase cells are indicated by closed circles, and open circles indicate BrdU negative cells (D). Notice that
S phase cells express low levels of cyclin D1. A few D1 3/3 cells with relatively high levels of cyclin D1 were in fact round mitotic cells dis-
playing non-speci¢c staining.
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(BrdU) pulse soon after the injection, and cyclin D1 expres-
sion in those cells was followed thereafter. Anti-Ras Ab in-
jection during S phase completely blocked the high expression
of cyclin D1 which would have occurred in the next G2 phase,
con¢rming the Ras requirement for cyclin D1 elevation during
G2 phase. A similar analysis combined with time-lapse anal-
yses to determine the cell cycle timing of the anti-Ras injection
revealed that once induced during G2 phase in a Ras-depen-
dent manner, cyclin D1 expression continued through G1
phase without Ras activity [43]. Finally, as we predicted,
forced expression of cyclin D1 partially overcame the Ras
requirement for cell cycle continuation, indicating that one
of the primary functions of Ras activity in cyclin cells is to
induce cyclin D1 expression to drive G1/S transition [43]. In
each case, the predictions of our model were con¢rmed.
The continued expression of cyclin D1 during G1 phase in
the absence of Ras activity raises interesting questions. This
might result from the fact that each signaling step from acti-
vated Ras to cyclin D1 expression has a given half-life. The
overall half-life of cyclin D1 expression following Ras neutral-
ization is an integration of the half-lives of individual signal-
ing steps, which together serve as a reservoir for the total
signaling activity. Thus, molecules of the ¢rst step must be
inactivated before their de¢ciency initiates decay of the activ-
ities in the second signaling step and so forth. In this way the
expression of cyclin D1 can persist even after Ras neutraliza-
tion, despite the fact that induction of cyclin D1 expression is
dependent upon Ras. Alternatively, cell cycle speci¢c altera-
tions in Ras signaling might reduce the Ras dependency of
cyclin D1 expression during G1 phase. JunB, which represses
cyclin D1 transcription by antagonizing c-Jun, is phosphory-
lated by cdc2 during mitosis. It is suggested that this phos-
phorylation triggers the degradation of JunB resulting in low
expression levels during G1 phase [62]. With low levels of this
repressor, Ras activity might be required to a lesser extent for
cyclin D1 expression during G1 phase. The third possibility is
that Ras is required only to activate cyclin D1 expression,
while Ras-independent mechanisms promote its continued ex-
pression. In support of this idea, many signaling systems have
been reported to activate the cyclin D1 promoter [63^70].
Finally, the stability of cyclin D1 protein might play a role
in this continued expression in G1 phase. Cyclin D1 is actively
degraded through ubiquitination [71]. Phosphorylation by gly-
cogen synthase kinase 3L (GSK3L) triggers degradation of
cyclin D1. During G1 phase, GSK3L is mainly localized in
the cytoplasm whereas cyclin D1 is concentrated in the nu-
cleus [72]. This subcellular separation of GSK3L from cyclin
D1 would favor the stabilization of cyclin D1, contributing to
its Ras-independent expression during G1 phase.
6. The biological signi¢cance of cyclin D1 expression in
G2 phase
Cyclin D1 is known as a G1 cyclin because it plays an
important role in the cell cycle transition from G1 to S phase.
The high levels of cyclin D1 expression during G2 phase,
Fig. 3. G2 arrest induced by anti-cyclin D1 Ab injection. Rapidly growing NIH3T3 cells were injected with anti-cyclin D1 Ab, anti-Ras Ab or
non-immune chicken IgG. After the indicated times, cells were ¢xed and DNA was stained with DAPI. To detect injected cells, injected IgG
was stained. Non-immune IgG injection did not alter the DNA histogram pattern (A). When cells received anti-Ras Ab, the majority of the
cells were arrested at G1 phase by 12 h (B). Anti-cyclin D1 Ab, on the other hand, induced G2 arrest at 12 h after injection (C). This arrest
subsided by 24 h (D).
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however, prompted us to consider the possibility that cyclin
D1 has a biological role during G2 phase. From our previous
studies, it was clear that anti-cyclin D1 Ab injection did not
induce a prolonged G2 phase arrest [44]. It is possible, how-
ever, that a slight delay of cell cycle progression might be seen
following anti-cyclin D1 Ab injection. Therefore, in order to
carefully determine if cyclin D1 plays some role in progression
through G2 phase, neutralizing Ab against cyclin D1 was
injected into rapidly growing cells and the DNA content of
the injected cells was determined as a function of time after
the injection. For comparison, anti-Ras Ab or non-immune
chicken IgG was injected into parallel cultures. Non-immune
IgG injection did not change the cell cycle distribution at any
time (Fig. 3A). G1 arrest became obvious 12 h after anti-Ras
injection (Fig. 3B). In contrast, the G2 population increased
at 12 h after anti-cyclin D1 injection (Fig. 3C). This increase
was not very large, but similar results were obtained in multi-
ple experiments. This delay in G2 phase progression, however,
is temporary, because the G2 population decreased with time
(Fig. 3D).
Since cyclin D1 protein is unstable, it is possible that its
continued synthesis following injection had begun to saturate
the neutralizing capacity of the injected Ab. This might result
in a gradual release of cell cycle blockage in G1 phase, and
allow for the appearance of G2 phase cells 15 h following
injection of anti-cyclin D1 seen above. To avoid this potential
complication we performed a time-lapse experiment. Cells
were followed for 15 h prior to and following injection with
anti-cyclin D1 Ab, and pulsed with 3H-thymidine at the end
of the analysis to determine cells in S phase. The DNA con-
tent of each cell was determined by image analysis following
DAPI staining and the time-lapse movies were analyzed to
determine the age of each cell at the end of the analysis.
This analysis allowed us to determine approximate cell cycle
position at the time of injection, and the ability of cells to pass
through the cell cycle thereafter (Fig. 4).
The results con¢rm the conclusions from previous experi-
ments and indicate that injected anti-cyclin D1 does interfere
with passage through G2 phase. Many cells in G2 and S
phases at the time of injection were found in G2 phase at
the end of the experiment without ever passing through mi-
tosis. These cells had, therefore, been retained in G2 phase by
the injected Ab for 20^30 h (Fig. 4A). Cells in G1 phase at the
time of injection had either been retained in G1 phase, or had
recently been released from the G1 block and had entered S
phase. This observation con¢rms the transient nature of the
anti-cyclin D1 blockage. Cells that divided following injection
are listed with negative ages. Most of these cells had G1 DNA
content as a result of anti-cyclin D1 inhibition (Fig. 4A). As a
control, anti-Ras Ab did not inhibit progression through G2
phase. Most of these injected cells divided following injection
and were retained with a G1 DNA content (Fig. 4B). While
cyclin D1 production is dependent upon Ras activity, it is
apparent that anti-Ras was not able to decrease cyclin D1
levels enough to inhibit G2 transit within the time frame of
this experiment. Taken together, these experiments indicate
that when cyclin D1 levels are eliminated by anti-cyclin D1
Ab injection, G2 phase is increased in length by up to 10 h.
Recently, abrogation of cyclin D1 or inhibition of cyclin D-
associated kinase has been shown to cause G2 arrest [73,74]
and over-expression of cyclin D1 is reported to shorten the G2
arrest induced by Q-irradiation [75]. It is therefore possible
that high levels of cyclin D1 expression during G2 phase
might facilitate progression through G2 phase.
7. Synchronization alters the nature of cell cycle control
In order to perform the studies described above, it was
necessary to analyze individual cells in asynchronous culture.
It would be desirable to con¢rm these conclusions with bio-
chemical analyses in synchronous cultures. Our goal was to
con¢rm our observation with biochemical means, such as
Western or Northern blotting using synchronous cultures.
Fig. 4. Neutralization of cyclin D1 slows down the progression
through G2 phase. A: An asynchronous culture of NIH3T3 cells
was monitored in time-lapse for 15 h to determine the cell cycle
timing of anti-cyclin D1 injection. After the injection, a second 15 h
time-lapse movie was taken, with a 3H-thymidine pulse during the
¢nal hour. Cells were ¢xed and stained with DAPI for determina-
tion of DNA content. Age of the cells at the time of injection is
plotted against DNA content. Thymidine-labeled cells are indicated
by closed circles, and non-labeled cells with open circles. The cells
with negative age divided following the injection. For example, a
cell with the age of minus 6 h divided 6 h after the injection. The
cells with positive age divided at the indicated times prior to the in-
jection and never divided thereafter until the end of the experiment.
The cell cycle bar at the top indicates the cell cycle position at the
time of injection, estimated from the age of the cell. The cell cycle
bar on the right indicates the cell cycle phase at the end of the ex-
periment, determined by the intensity of DAPI staining. A signi¢-
cant number of anti-cyclin D1-injected cells had G2 content of
DNA at the end of the experiment. The majority of such cells re-
ceived injection while they were in S or G2 phase. This indicates
that these cells stayed in S or G2 for at least 15 h after the injec-
tion. B: Under the same conditions, anti-Ras Ab injection did not
show any signi¢cant G2 population at the end of the experiment,
indicating no G2-arresting activity of this Ab.
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Although synchronization may alter the nature of cell cycle,
the second cell cycle phases after the release from serum star-
vation may be similar to those in rapid cell cycle. For exam-
ple, the expression of c-myc in the second G1 phase following
release from quiescence is similar to the constitutive expres-
sion observed in G1 phase of rapidly growing cultures [36,37].
We tested the cyclin D1 expression from G2 through the
second G1 phase following serum stimulation of quiescent
NIH3T3 cells. Using the methods described above, we ana-
lyzed cell cycle synchrony, cyclin D1 expression pattern and
the Ras dependency of cyclin D1 expression to determine if
the regulation of cyclin D1 was similar to an asynchronous
culture. Judging by DNA content, the cell cycle synchrony
was maintained well even at 21 h after serum stimulation,
when the majority of cells had progressed into G2 phase
(Fig. 5A). These synchronous G2 cells expressed high levels
of cyclin D1, and the high levels of expression were main-
tained through the next G1 phase (the second G1), 24 h after
serum addition (Fig. 5B). This expression pattern of cyclin D1
was the same as in rapidly growing asynchronous cultures.
Next we examined the Ras dependency of the cyclin D1 ex-
pression during G2 and the second G1 phases. Anti-Ras Ab
was injected at 21 h after the serum stimulation, the time
point when the majority of cells had progressed into G2 phase
and expressed high levels of cyclin D1. When the cells were
¢xed 3 h after the injection, i.e. 24 h after the serum addition,
anti-Ras injection suppressed the level of cyclin D1 expression
in both G1 and G2 populations (Fig. 5C). In a rapidly grow-
ing culture, on the other hand, cyclin D1 expression continued
through G1 at least for 6 h after anti-Ras injection, once it
has been induced during the preceding G2 phase in a Ras-
dependent manner [44]. This indicates that serum starvation
altered the Ras dependency of cyclin D1 expression in the
second G1 phase.
We also tested the synchronized cultures released from S
phase arrest induced by double thymidine block or aphidicho-
lin^thymidine block. One previous report observed that cyclin
D1 is induced as the cells progressed into G2 phase following
release from S phase arrest [61]. Our image analysis detected
the same increase in cyclin D1 protein expression as the cells
synchronously progress into G2 phase as was observed in
asynchronous cultures. Under these conditions, however, the
cyclin D1 expression in the next G1 phase again became de-
pendent upon Ras activity (data not shown). In mitotic shake
o¡, we could not achieve enough synchrony to perform bio-
chemical analysis after the cells passed through the S phase.
Therefore, no synchronization protocol tested faithfully repro-
duced the delicate control patterns of cyclin D1 through the
cell cycle as seen in continuous cell cycle progression. These
results emphasize the importance of our methods to analyze
rapidly proliferating cells without synchronization.
8. Conclusion
Based upon these results, the following model is proposed
(Fig. 6). During continuous cell cycle progression, cells sense
the presence of mitogens leading to Ras activation during G2
phase or earlier. Activated Ras induces cyclin D1 expression
during G2 phase. Once induced by Ras action, cyclin D1
expression continues until the beginning of the next S phase
in a Ras-independent fashion. This Ras-independent contin-
ued expression of cyclin D1 drives, in part, cell cycle progres-
sion from G1 to S phase even when the activity of Ras is
abrogated during G1 phase. In this way, anti-Ras injection
during G1 phase failed to arrest rapidly cycling NIH3T3 cells
in the current G1. In other words, the Ras-dependent decision
to pass through the G1/S transition is already made during
the preceding G2 phase.
It seems that rapidly proliferating cells start to prepare for
the next G1/S transition while they are still in G2 phase, so
long as the conditions remain favorable for proliferation.
Such early preparation may allow for a shortened G1 phase.
In support of this model, we recently observed that the ele-
vation of cyclin D1 expression levels took place only in G2
Fig. 5. Synchronization alters Ras dependency of cyclin D1 expression. NIH3T3 cells were made quiescent by serum starvation (0.5% serum)
for 2 days. Cells were stimulated with 10% serum. At indicated time after serum addition, cells were ¢xed and stained for cyclin D1 and DNA
with immuno£uorescence and DAPI. The intensity of cyclin D1-associated £uorescence was plotted against DNA content. Each circle repre-
sents a single cell. After 21 h, cells progress into G2 phase with good synchrony and cyclin D1 levels are high (A). At this time point, anti-Ras
Ab was injected and further cultured for 3 h, during which half the cells completed mitosis. Anti-Ras Ab suppressed the cyclin D1 expression
levels both in G1 and G2 phase (C) in comparison to non-injected surrounding cells (B). This is quite di¡erent from rapidly cycling cells, where
anti-Ras Ab injection failed to suppress the already induced cyclin D1 in G1 phase [43].
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phase when oncogenic Ras was injected [51]. The expression
of cyclin D1 during G2 also promotes rapid passage through
G2 phase contributing to a shortened cell cycle. Although Ras
becomes dispensable after mitosis in asynchronous cultures,
the cyclin D1-dependent and protein synthesis-dependent re-
striction point exists at the end of the G1 phase, and serum is
still required during early G1 phase for the completion of the
next cell cycle [44]. These requirements may serve as G1 check
points to monitor the concerted activities of molecules re-
quired for G1/S transition, preventing the premature or un-
desirable entry into S phase during the rapid cell cycle pro-
gression.
This new concept concerning the control of continuous cell
cycle progression was obtained because the utilized analytical
methods, which were designed to analyze continuously prolif-
erating cells, avoided the alterations in cell cycle signaling
caused by synchronization. By applying the methods de-
scribed here, it is possible that we may learn new aspects of
cell cycle control in cancer cells. Furthermore, we may even
identify di¡erences in proliferative signaling between cancer
cells and rapidly proliferating normal tissues such as epider-
mis, gut epithelium and bone marrow, which are often inad-
vertently targeted by cancer therapeutics. The information
obtained from such studies might suggest cancer therapeutic
strategies which are less toxic for these continuously prolifer-
ating normal tissues, without compromising the toxicity
against cancer cells.
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